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Abstract 
 
The syntheses of racemic and homochiral [4.4]-spirolactams, starting from L-proline, 
in good yields are described. Reduction of the lactam carbonyl group of spirolactams, 
containing chiral substituents on the lactam nitrogen, with lithium aluminium hydride, 
gives a series of homochiral [4.4]-spirodiamines. The crystal structure of one of these 
spirodiamines on complexation with zinc chloride was obtained. Interestingly it 
showed a hydrogen-bonded dimeric structure, where the monomers are 
diastereoisomeric diamines. 
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Introduction 
 
Diamines, especially vicinal diamines, are of interest because of their ability to 
strongly bind metal ions leading to Lewis acid complexes, which have found uses as 
catalysts in a wide range of organic syntheses.
1
 Many of the well known diamines, 
such as ethylenediamine (1, Figure 1), are acyclic and are very flexible in nature. The 
introduction of constraints into such structures is a well studied method for reducing 
this conformational flexibility giving molecules with a more defined 3-D structure 
[e.g., trans-1,2-diaminocyclohexane (2)
2
 is a constrained version of ethylenediamine]. 
In some cases this has been used in biologically active molecules to either increase the 
affinity of the molecule for its target (cyclic versus acyclic peptides),
3
 or to make the 
molecules more metabolically stable, which can lead to improved bioavailability.
4
 
The naturally occurring polycyclic diamine (-)-sparteine (3) has found use as a chiral 
ligand in a number of applications in asymmetric synthesis.
5
 Another method of 
constraint which has been used is to introduce a spiro fusion of two rings which forces 
the nitrogen atoms into a mutually orthogonal relationship (4, Figure 1).  
 
There are currently a large number of methods for the synthesis of spirocyclic 
compounds and they can also be easily formed in a stereocontrolled manner.
6
 
Freidinger was the first to incorporate a lactam constraint in the backbone of a peptide 
in order to rigidify the peptide tertiary structure into a more defined conformation.
7
 
One of the most common methods for the synthesis of lactams is the cyclisation of an 
amino group (primary or secondary) onto a carboxylic ester, with concomitant loss of 
an alcohol. The overall efficiency of the cyclisation is dependent on the size of the 
ring being formed, the nature of the amino substitutent in the case of a secondary 
amine, any substituents on the resulting ring and the structure of the alkyl moiety of 
the ester group. Many of the reactions take place spontaneously at ambient 
temperature, while others require heating in a suitable solvent.
8
  
 
L-Proline-derived spirolactams have in particular been studied for their use in 
constraining peptides with L-proline residues to mimic the -turn, a very important 
component of peptide secondary structure. Depending on their final use spirolactams 
are synthesised either as racemic mixtures or as single enantiomers. In most cases 
these syntheses start from L-proline which must then be alkylated in the -position. 
Full control of the stereochemistry can easily be achieved using Seebach’s “Self-
Reproduction of Chirality” methodology,9 whereas the racemic compounds simply 
require alkylation of the enolate of a suitably protected proline molecule which, after 
a series of further functional group manipulations, gives cyclisation precursors.  
 
A number of different strategies have also been used for the critical final cyclisation 
step to form the spirobicyclic lactam ring. These include (i) intramolecular amide 
coupling, with a coupling agent (e.g. DCC or EDC), of tethered secondary amines 
with the deprotected proline carboxylic acid group;
10
 (ii) cyclisation of proline 
carboxylic amides onto a primary alcohol under Mitsunobu conditions;
11
 and (iii) 
thermal cyclisation of a tethered secondary amine onto a proline carboxylic ester in 
DMF at 70 
o
C, although the yield of the latter reaction was very low (27%), with only 
one diastereoisomer cyclising and the side chain carboxylic acid subsequently being 
converted to the methyl ester by treatment with diazomethane (Figure 2).
12
 
 
Results and Discussion 
 
As part of a programme of research to synthesise both racemic and homochiral 
spirocycles, the synthesis of proline-derived [4.4]-spirolactams
13,15
  and their 
conversion to spirodiamines was of interest.  
 
The variety of different cyclisation methods used, along with their wide ranging 
yields, prompted us to study one of the methods, the thermal cyclisation reaction, in 
more detail in order to investigate whether it was a viable method for the synthesis of 
a range of proline-derived [4.4]-spirolactams. This necessitated the synthesis of 
secondary amines for subsequent cyclisation onto a carboxylic ester (Scheme 1).
13
  
 
The required secondary amines (9a-c) would be obtained by reductive amination of 
the racemic aldehyde 8, so the efficient synthesis of this aldehyde was critical to the 
overall success of this method, as a generalised route to spirolactams. 8 was prepared 
in 4 steps from L-proline by Boc protection of the nitrogen of the methyl ester of L-
proline, which was obtained quantitatively from L-proline by treatment with SOCl2 in 
methanol. The -allyl group was efficiently introduced in 80% yield.14 Oxidative 
cleavage of the alkene using OsO4/NaIO4 gave the aldehyde 8 in a 74% yield.
10e
 It 
was necessary to efficiently purify the aldehyde by column chromatography to free it 
from any traces of osmium by-products, as failure to do so led to major reductions in 
the yield of the subsequent reductive amination and cyclisation reactions, with a large 
amount of decomposition occurring. Reductive amination of 8 with allyl amine, gave 
the required secondary amine spirolactam precursor 9a. Following the method of 
Johnson
11a
, thermal cyclcisation of 9a in DMF at 70 
o
C gave the spirolactam 10a in a 
99% yield, though the work-up was lengthy. Cyclisation in refluxing toluene gave 10a 
in a 66% yield, with a simpler work-up procedure. When benzylamine was used in 
place of allyl amine, using the same reaction cyclisation conditions, the N-benzyl 
substituted spirolactam (10a) was obtained in a higher yield of 75%. 
 
Extension of this methodology using chiral -substituted amines would give pairs of 
diastereoisomeric spirolactams.
15
 Reductive amination of aldehyde 8 with either (R)- 
or (S)--methylbenzylamine gave spirolactams 11a & 11b (Scheme 2). Prolonged 
stirring of solutions of these compounds in refluxing toluene gave no indication of 
any cyclisation. In a similar cyclisation reaction of a secondary amine, where alanine 
methyl ester was used in the reductive amination step, Auberson et al. were able to 
successfully achieve cyclisation in yields of >90%, by stirring at reflux temperature in 
xylenes for 2 hours.
16
 Stirring solutions of amino esters 11a or 11b in refluxing 
xylenes, even for extended periods of time, gave no indication of any cyclisation 
reaction occurring. 
 
Treatment of toluene solutions of 11a or 11b with sodium amide (50% solution in 
toluene) at reflux temperature gave the desired spirolactams 12a-d (as pairs of 
diastereoisomers in 1:1 ratios), isolated in yields of 30% and 51%, from aldehyde 8. 
HPLC analysis of each diastereoisomer showed a high degree of purity (all greater 
than 98.8% pure). The only impurity identified, in each case, was the 
diastereoisomeric product produced in the reaction. 
 
It was not possible to obtain crystals suitable for X-ray analysis of any of the four 
diastereoisomers 12a-d. Although the stereochemistry of the -methyl benzyl 
substituent was known from the choice of the starting homochiral amine the absolute 
stereochemistry of the spiro centre in each case was not. Molecular modelling
17
 was 
used to give minimised energy conformations of the SR and RR diastereoisomeric pair 
(12a & 12b). It was immediately evident from the minimised structures (Figure 3) 
that in the SR diastereoisomer the hydrogens of the Boc protecting group and the meta 
hydrogens of the phenyl group were close in space (closest distance of 2.67 Å), 
whereas in the RR isomer the Boc and phenyl groups were a large distance apart. It 
was therefore expected that NOE NMR experiments would be able to distinguish 
between the two diastereoisomers. Irradiation of the signal for the hydrogens of the 
Boc group of the diastereoisomer assigned as SR showed an NOE to the phenyl 
hydrogens, whilst no similar NOE was observed in the case of the RR 
diastereoisomer, though this is not conclusive proof of the absolute stereochemistry of 
the spiro centre. 
 
The homochiral diamines derived from the spirolactams 12a-d were obtained when 
the N-Boc protecting group was cleanly removed from each spirolactam to give the 
free amino spirolactams 13a-d, and the reduction of the lactams was then examined. 
The optimal conditions found for successful reduction was the use of 20 molar 
equivalents of lithium aluminium hydride in THF (Scheme 3), which gave the 
diamines 14a-d in acceptable isolated yields (43-56%).  
 
One of our interests is in the use of these diamines as ligands for metal ions, thus 
giving chiral complexes which may have potential as novel chiral catalysts in 
asymmetric transformations. The first step was to examine whether the amines bound 
to a metal ion. No complexation was observed when ethanolic solutions of the amines 
were treated with copper(II) acetate. Zinc(II) was then chosen as it is diamagnetic, 
making studies of complexation also possible by NMR spectroscopy. When ethanolic 
solutions of amines 14a-d were refluxed with 1.5 molar equivalents of ZnCl2 and the 
solutions were left standing at room temperature, the solutions containing amines 14a 
and 14b each gave one small single crystal (15a and 15b) suitable for X-ray analysis. 
The surprise result from these studies was that the X-ray crystal structures of the zinc 
complexes 15a and 15b were identical (Figure 3). 
 
Close examination of the X-ray structures shows that a 1:1 dimeric complex had 
formed where each spirodiamine accommodates one zinc metal. The asymmetric unit 
of the crystal contains two independent molecules linked into a hydrogen-bonded 
dimer. Each zinc atom occupies a pseudo-tetrahedral geometry, where it is complexed 
to the two nitrogens of the spirocycle and to two chlorine atoms. The N-Zn-N angle is 
84.4(2)
o
  in both molecules of the dimer, and the Cl-Zn-Cl angle is 120.71(7)
 o
 in one 
molecule while it is 119.11(7)
o
 in the other. The dimer is then formed by two 
intermolecular hydrogen bonds via one of the chlorine atoms and an amine N-H. The 
nitrogen to chlorine distances for the two hydrogen bonds are 3.355(6) and 3.372(6) 
Å. The important bond lengths and angles are shown in Table 1. The formation of a 
dimer may not in itself unusual, but the most intriguing aspect of the crystal structure 
is that the two spirodiamines that make up the dimer are diastereoisomeric. This result 
was certainly not anticipated as purification of each precursor amine (14a-d) was 
carried out very carefully. HPLC analysis showed that there was only a very small 
amount of the corresponding disatereoisomer present in the “purified” amines. In the 
case of 14a it was shown to be 98.7% pure with 1.2% of 14b being present. Therefore 
on complexation with zinc chloride the vast majority of complexed diamine 14a 
remained in solution with only a small amount crystallising out with the opposite 
diastereoisomeric diamine “impurity” 14b. Also by HPLC analysis amine 14b was 
found to be 99.3% pure, contaminated with only 0.7% of the diasteresoisomer 14a. 
Again on complexation with zinc chloride the same result was obtained as before. 
 
Thus the ability of the chiral spirodiamines to complex a selected metal ion has been 
demonstrated. Mukaiyama has studied the asymmetric catalysis of the aldol reaction 
(Mukaiyama aldol) using diamines derived from L-proline, which are complexed to 
tin(II) triflate, as asymmetric catalysts (Figure 4).
18
 Using molecular modelling,
17
 
when the proline-derived diamine 16 was bound to zinc chloride and was minimised, 
the N-N distance was calculated to be 2.77 Å. From the crystal structure of complex 
15a it is observed that the N-N distances are 2.797 Å and 2.798 Å. Thus these 
distances compare very favourably with the calculated value for the Mukaiyama 
ligand 16, above. This leads us to believe that the spirodiamines 14a-d have the 
potential to be used as ligands for Sn
2+
, with the resulting complexes being used as 
catalysts in the asymmetric Mukaiyama aldol reaction. It is also envisaged that the 
spirodiamines will complex other metal ions, and thus have applications in metal 
catalysed asymmetric synthetic reactions. It is also envisaged that the homochiral 
spirolactams 13a-d will have applications as novel organocatalysts. All of these 
studies are currently being undertaken. 
 
Conclusions. 
 
In conclusion, a series of homochiral spirolactams derived from L-proline have been 
prepared. These spirolactams were reduced to spirodiamines using lithium aluminium 
hydride as reductant, and the diamines formed complexes with zinc chloride. The X-
ray crystal structure of one of these complexes showed an unusual dimeric form 
where the two spirodiamines present were diastereoisomeric. The properties of these 
spirodiamines are currently being further elucidated and their potential as ligands for 
metals to act as catalysts in asymmetric synthesis is currently being undertaken. The 
results of these studies will be reported in due course. 
 
Experimental. 
 
Allyl bromide was purified by passing it through a plug of activity III basic alumina. 
TLC was performed on Merck silica gel 60F254 plates and column chromatography 
was performed on Aldrich silica gel, 70-230 mesh, 60Å. 
1
H and 
13
C NMR ( ppm; J 
Hz) spectra were recorded on a Jeol JNM-LA300 FT-NMR spectrometer using CDCl3 
solutions with Me4Si as internal reference, unless otherwise indicated, with 
resolutions of 0.18 Hz and 0.01 ppm, respectively. CHCl3 was used to remove last 
traces of ethyl acetate from some samples. The last trace of CHCl3 persisted even 
after prolonged heating in vacuo and in these cases was visible in NMR spectra and 
microanalysis. Infrared spectra (cm
-1
) were recorded as KBr discs or liquid films 
between NaCl plates using a Nicolet Impact 410 FT-IR. Melting points were obtained 
on a Bibby Stuart Scientific SMP1 melting point apparatus and are uncorrected. 
Microanalyses were carried out at the Microanalytical Laboratory of University 
College Dublin. Mass spectra were obtained in the Centre for Synthesis and Chemical 
Biology, School of Chemistry and Chemical Biology, University College Dublin. X-
ray crystal structures were obtained in the Chemistry Department, Loughborough 
University, Loughborough, UK. HPLC analysis were carried out using methods on a 
Shimadzu HPLC system Class-VP, incorporating a LC-10AD pump, SPD-M10AVP 
Diode Array Detector, Auto-injector SIJ-10A with a system controller SCL-10A VP. 
Polarimetry was carried out at Dublin City University (DCU), using a Perkin-Elmer 
343 with cell path-length of 100 mm at 20 
o
C. 
 
N-Boc-L-proline methyl ester (6).
14
 
6 was prepared from L-proline by the method of Confalone.
14
 Microanalysis: Found 
C, 57.51; H, 8.60; N, 5.88. Calculated for C11H19NO4: C, 57.60; H, 8.34; N, 6.10. 
 
-Allyl N-Boc-proline methyl ester (7).14 
7 was prepared from 6 by the method of Confalone,
14
 except a 1M solution of 
LiHMDS in tetrahydrofuran, instead of hexane, was used as the base.  Microanalysis: 
Found C, 62.29; H, 8.80; N, 4.95. Calculated for C14H23NO4: C, 62.43; H, 8.61; N, 
5.20. 
 
()--Formylmethyl N-Boc-proline methyl ester (8).10e 
8 was prepared from 7 by the method of Johnson.
10e
 Microanalysis: Found C, 53.59; 
H, 7.60; N, 4.22. Calculated for C14H23NO4 (0.33 CHCl3): C, 53.43; H, 7.40; N, 4.67. 
 
7-Allyl-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylic acid tert-butyl ester 
(10a) Method A: To a stirred solution of 8 (0.10 g, 0.35 mmol) in ethanol (3 ml) 
under nitrogen, was added dropwise allyl amine (0.030 ml, 0.35 mmol), over 10 min 
at ambient temperature, and the solution was stirred for 2 h. Sodium borohydride 
(0.020 g, 0.42 mmol) was added in small portions over 5 min and the resulting 
solution was stirred at ambient temperature for 48 h. Water (30 ml) was added and the 
mixture was extracted with ethyl acetate (3 x 15 ml), and the combined organic layers 
were washed with brine (2 x 15 ml), dried over MgSO4 and concentrated in vacuo. 
The residue was dissolved in DMF (5 ml) under nitrogen, to which triethylamine 
(0.050 ml, 0.35 mmol) was added. The solution was stirred at 70 
o
C for 24 h, poured 
into water (50 ml) and extracted with ethyl acetate (3 x 20 ml). The combined organic 
layers were washed with 10% citric acid solution (2 x 20 ml), water (4 x 20 ml), brine 
(2 x 20 ml), dried over MgSO4 and concentrated in vacuo giving 10a as an oil 
(0.092g, 99%). Rf 0.21, 40% ethyl acetate/hexane. IR (thin film)/cm
-1
 2986, 1682, 
1388, 901. 
1
H NMR (two rotamers present)  5.81-5.66 (m, 1H, olefin CH), 5.26-5.16 
(m, 2H, olefin CH2), 4.13-4.01 (m, 1H, allyl CH2), 3.85-3.67 (m, 1H, allyl CH2), 3.57-
3.47 (m, 2H, pyrrolidine -CH2), 3.41-3.14 (m, 2H, lactam -CH2), 2.70-2.41 (m, 2H, 
lactam -CH2), 2.12-1.80 (m, 4H, pyrrolidineand -CH2), 1.44 and 1.42 (2 x s, 
9H, t-butyl). 
13
C NMR  174.24 and 174.20 (lactam carbonyl), 154.0 and 153.6 (Boc 
carbonyl), 136.6 and 136.2 (olefin CH), 118.6, 117.9 (olefin CH2), 80.0 and 79.5 (t-
butyl Cq), 67.0 and 66.7 (spiro Cq), 48.0 and 47.7 (allyl CH2), 46.1 (pyrrolidine -
CH2), 43.1 and 42.7 (lactam -CH2), 37.6 and 37.1 (lactam -CH2), 31.0 and 30.2 
(pyrrolidine -CH2), 28.6 (t-butyl CH3), 23.4 and 22.7 (pyrrolidine-CH2). 
Microanalysis: Found C, 57.81; H, 7.98; N, 8.60. Calculated for C15H24N2O3 (0.5 
CHCl3): C, 57.76; H, 7.66; N, 8.69. 
 
Method B: To a stirred solution of allylamine (0.37 ml, 4.9 mmol) in dry methanol (7 
ml) was added a solution of 8 (1.20 g, 4.4 mmol) in dry methanol (1.5 ml). 
Magnesium sulphate (0.316 g, 2.6 mmol) was added to the solution after 3 h and the 
solution was then stirred for a further 2 h. The reaction was cooled to -4 
o
C and 
NaBH4 (0.294 g, 7.8 mmol) was added portionwise. The reaction was quenched after 
1 h with a saturated solution of NaHCO3 (5 ml) and water (5 ml). The mixture was 
extracted with ethyl acetate (3 x 30 ml) then dried over MgSO4 and concentrated in 
vacuo. The resulting oil was stirred at reflux temperature in toluene (15 ml) for 16 h. 
After cooling to ambient temperature the solution was concentrated in vacuo giving 
an oil which was purified on silica gel in 10% ethyl acetate/hexane to give a pale 
yellow oil (0.685 g, 60%). For analysis see Method A. 
 
7-Benzyl-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylic acid tert-butyl ester 
(10b) Method A: Prepared by a similar method to 10a (method A) using benzylamine 
giving a pale yellow oil (88% yield). Rf 0.12, 40% ethyl acetate/hexane. IR (thin 
film)/cm
-1
: 3000, 2950, 1700, 1680. 
1
H NMR (two rotamers present)  7.35-7.22 (m, 
5H, aromatic), 4.90 (d, 1H, J = 14.7 Hz, benzyl CH2), 4.72 (d, 1H, J = 14.4 Hz, 
benzyl CH2), 4.28 (d, 1H, J = 15 Hz, benzyl CH2), 3.97 (d, 1H, J = 14.5 Hz, benzyl 
CH2), 3.62-3.42 (m, 2H, pyrrolidine -CH2), 3.34-3.03 (m, 2H, lactam -CH2), 2.66-
2.39 (m, 1H, lactam -CH2), 2.21-2.08 (m, 1H, lactam -CH2), 2.06-1.95 (m, 2H, 
pyrrolidine-CH2), 1.89-1.76 (m, 2H, pyrrolidine-CH2), 1.46 and 1.39 (2 x s, 9H, t-
butyl). 
13
C NMR (two rotamers present)  174.5 and 174.4 (lactam carbonyl), 153.5 
and 153.4 (Boc carbonyl), 136.6 (ipso aromatic), 128.7, 128.4 and 128.3 (aromatic 
CH), 80.0 and 79.5 (t-butyl Cq), 67.0 and 66.9 (spiro Cq), 48.0 and 47.8 (benzyl CH2), 
47.5 and 47.4 (lactam -CH2), 42.9 and 42.7 (pyrrolidine -CH2), 37.8 and 37.1 
(lactam -CH2), 30.9 and 30.8 (pyrrolidine -CH2), 28.5 (t-butyl CH3), 23.4 and 22.8 
(pyrrolidine-CH2). Microanalysis: Found C, 62.55; H, 7.39; N, 7.14. Calculated for 
C15H24N2O3 (0.5 CHCl3): C, 62.73; H, 7.42; N, 7.50. 
 
Method B: 10b was prepared by a similar method to that used for 10a (Method B) 
giving a pale yellow oil (1.46 g, 75%) after purification on silica gel in 15% ethyl 
acetate/hexane. For analysis see method A. 
 
(5S) and (5R)-6-Oxo-7-((1’R)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane-1-
carboxylic acid tert-butyl ester (12a and 12b). 
To a stirred solution of (R)-(+)-1-phenylethyl amine (1.29 ml, 10.1 mmol) in dry 
methanol (6 ml) was added a solution of aldehyde 8 (2.5 g, 9.22 mmol) in dry 
methanol (2 ml). After 1 h of stirring at ambient temperature, magnesium sulphate 
(0.66 g, 5.5 mmol) was added to the solution and stirring was continued for 4 h. The 
reaction was cooled to –4 oC and NaBH4 (0.56 g, 15 mmol) was added portionwise 
over 10 min. The reaction was quenched after 1 h at ambient temperature with a 
saturated solution of NaHCO3 (7 ml) and water (3 ml). The aqueous layer was 
extracted with ethyl acetate (3 x 30 ml), dried over MgSO4 and concentrated in vacuo 
to give a yellow oil (2.10 g). The resulting oil was stirred at reflux temperature for 24 
h in toluene (20 ml) in the presence of 50% sodium amide (suspension) in toluene 
(0.20 ml, 5.2 mmol). After cooling to ambient temperature the solution was quenched 
with H2O (4 ml), and extracted with ethyl acetate (3 x 20ml). The combined organics 
were then concentrated in vacuo to give a colourless oil (0.909 g, 30%), which was 
purified by flash column chromatography on silica gel in 10% ethyl acetate/hexane 
resulting in 12a (0.491 g, 54%) as a white solid. Rf 0.78 (60% ethyl acetate/hexane). 
Mp 92-96 
o
C. IR (KBr)/cm
-1
 3031, 2976, 1702, 1682, 1361. 
1
H NMR  (two rotamers 
present) δ 7.35-7.25 (m, 5H, aromatic), 5.77-5.49 (m, 1H, -CH), 3.58-3.44 (m, 2H, 
pyrrolidine -CH2), 3.42-3.23 (m, 1H, lactam -CH2), 2.79-2.67 (m, 1H, lactam -
CH2), 2.61-2.37 (m, 1H, lactam -CH2), 2.13-1.66 (m, 5H, pyrrolidine - and -CH2, 
and lactam -CH2), 1.58 and 1.56 (2 x d, 3H, J = 9.87 Hz, -CH3), 1.48  and 1.46 (2 x 
s, 9H, t-butyl CH3). 
13
C
 
NMR δ (two rotamers present) 174.1 (C=O, lactam), 153.5 
(C=O, Boc), 140.4 (ipso aromatic), 128.4 (meta), 127.6 (ortho), 127.1 (para), 80.0 
and 79.4 (t-butyl Cq), 67.3 (spiro Cq), 49.6 and 49.2 (-CH), 48.1 and 47.8 
(pyrrolidine -CH2), 38.6 and 37.9 (CH2, lactam -CH2), 36.9 and 36.6 (CH2, 
pyrrolidine -CH2), 30.4 and 29.9 (lactam -CH2), 28.5 and 28.4 (t-butyl CH3), 23.3 
and 22.4 (CH2, pyrrolidine -CH2), 15.6 and 15.5 (-CH3). Microanalysis: Found C, 
69.87; H, 8.49; N, 7.86. Calculated for C20H28N2O3: C, 69.74;  H, 8.16;  N, 8.13. 
 12b was obtained as a white solid. Rf 0.68 (60% ethyl acetate/hexane). Mp 128-132 
o
C. IR (KBr)/cm
-1
 3032, 2975, 1700, 1685, 1360. 
1
H NMR (two rotamers present) δ 
7.45-7.22 (m, 5H, aromatic), 5.48 (q, 0.5H, J = 7.14 Hz, -CH), 5.38 (q, 0.5H, J = 
7.14 Hz, -CH), 3.61-3.48 (m, 2H, pyrrolidine -CH2), 3.19-3.03 (m, 2H, lactam -
CH2), 2.58-2.37 (2x m, 1H, lactam -CH2), 2.17-1.76 (m, 5H, pyrrolidine - and -
CH2, and lactam -CH2), 1.50 and 1.48 (2 x d, 3H, J = 14.28 Hz, -CH3), 1.46 and 
1.26 (2 x s, 9H, t-butyl CH3). 
13
C
 
NMR (two rotamers present) δ 174.4 and 174.2 
(C=O, lactam), 153.5 (C=O, Boc), 140.1 (ipso aromatic), 127.64 (meta), 127.61 
(ortho), 127.5 (para), 80.3 and 79.5 (spiro Cq), 67.5 and 67.4 (t-butyl Cq), 50.9 and 
49.5 (-CH), 48.6 and 48.2 (CH2, pyrrolidine -CH2), 38.9 and 38.7 (CH2, lactam -
CH2), 37.5 and 37.1 (CH2, pyrrolidine -CH2), 30.4 and 30.1 (CH2, lactam -CH2), 
28.8 and 28.5 (CH3, (t-butyl CH3), 23.6 and 22.6 (CH2, pyrrolidine -CH2), 16.6 and 
16.4 (CH3, (-CH3). Microanalysis: Found C, 70.38; H, 8.65; N, 7.53. Calculated for 
C20H28N2O3: C, 69.74;  H, 8.16;  N, 8.13. 
 
(5R) and (5S)-6-Oxo-7-((1’S)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane-1-
carboxylic acid tert-butyl ester (12c and 12d). 
Prepared by a similar method to the preparation of 12a and 12b using (S)-(-)-1-
phenylethyl amine in 51% yield. 12c was obtained as a white solid. Analytical data 
were the same as 12b. Microanalysis: Found C, 69.68; H, 8.14; N, 8.05. Calculated 
for C20H28N2O3: C, 69.74;  H, 8.16;  N, 8.13.  
 
12d was obtained as a white solid. Analytical data were the same as 12a. 
Microanalysis:  Found C, 69.49; H, 8.14; N, 7.89. Calculated for C20H28N2O3: C, 
69.74;  H, 8.16;  N, 8.13.  
  
(5S)-6-Oxo-7-((1’R)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13a). 
 To a stirred solution of 12a (0.270 g, 0.78 mmol) in DCM (2.7 ml) was added TFA 
(2.7 ml) and the resulting solution was stirred for 2 h at ambient temperature. The 
solution was basified to pH 10 with aqueous 3 M KOH solution, and extracted with 
chloroform (2 x 30 ml). The combined organic layers were washed with brine (2 x 20 
ml), dried over MgSO4 and concentrated in vacuo giving a yellow oil (0.169 g, 89%). 
Rf  0.24  (10% methanol/ethyl acetate). [α]
20
D
 
+9616.6 (c = 0.0180, methanol). IR (thin 
film)/cm
-1
 3329, 2972, 2876, 1682. 
1
H NMR  7.36-7.26 (m, 5H, aromatic), 5.50-5.46 
(q, 1H, J = 6.93 Hz, -CH), 3.29-3.20 (m, 2H, pyrrolidine -CH2), 2.98-2.90 and 
2.84-2.76 (m x 2, 2H, lactam -CH2),  2.06 (s (br.), 1H, N-H), 2.01-1.74 (m, 6H, 
pyrrolidine - and -CH2, and lactam -CH2), 1.55 (d, 3H, J = 7.14 Hz, -CH3). 
13
C 
NMR  176.74 (C=O, lactam), 140.0 (ipso aromatic), 128.5 (meta), 127.5 (ortho), 
126.9 (para), 67.9 (spiro Cq), 49.4 (-CH), 47.5 (lactam -CH2), 39.0 (pyrrolidine -
CH2), 35.2 (CH2, pyrrolidine -CH2), 34.8 (lactam -CH2), 26.1 (pyrrolidine -CH2), 
16.0 (-CH3). 
 
(5R)-6-Oxo-7-((1’R)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13b). 
This was prepared from 12b, by the method used for 12a. 73% yield as a light yellow 
oil.  Rf  0.26  (10% methanol/ethyl acetate). [α]
20
D
 
+13211.3
o
 (c = 0.0246, methanol). 
IR (thin film)/cm
-1
  3484, 2970, 2876, 1682. 
1
H NMR  7.36-7.26 (m, 5H, aromatic), 
5.46-5.39 (q, 1H, J = 7.14 Hz, -CH), 3.34-3.15 (m, 2H, pyrrolidine -CH2),  3.08-
2.94 (m x 2, 2H, lactam -CH2), 2.77 (s (br.), 1H, N-H), 2.04-1.73 (m, 6H, pyrrolidine 
- and -CH2, and lactam -CH2), 1.55 (d, 3H, J = 7.14 Hz, -CH3). 
13
C NMR  
175.9 (C=O, lactam), 139.0 (ipso aromatic), 128.6 (meta), 127.5 (ortho), 126.9 
(para), 68.1 (spiro Cq), 49.6 (CH, -CH), 47.2 (lactam -CH2), 39.1 (pyrrolidine -
CH2), 35.1 (pyrrolidine -CH2), 34.2 (lactam -CH2), 25.7 (CH2, pyrrolidine -CH2), 
16.3 (CH3, -CH3). 
 
(5R)-6-Oxo-7-((1’S)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13c). 
This was prepared from 12c, by the method used for 12a. 76% yield as a light yellow 
oil. Analytical data were the same as 13a. 
 
(5S)-6-Oxo-7-((1’S)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13d). 
This was prepared from 12d, by the method used for 13a. 80% yield as a light yellow 
oil. Analytical data were the same as 13b. 
 
(5S)-7-((1’R)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14a). 
To a stirring solution of lithium aluminium hydride 1 M solution in THF (14.8 ml, 
14.8 mmol) in dry THF (5ml) at -20 
o
C under nitrogen, was added a 13a (0.179 g, 
0.74 mmol) in dry THF (1 ml) and the solution was allowed to warm to ambient 
temperature and stirred for 48 h. To the reaction mixture, saturated sodium chloride 
solution and 50% sodium hydroxide solution were added alternately (each time 
adding 3 drops), until no hydride was left (i.e. until the solution did not vigorously 
react). The solution was then filtered, washing the precipitate thoroughly with 
chloroform (3 x 20ml). The combined washings were dried over K2CO3 and 
concentrated in vacuo giving a yellow oil, which was purified on preparative TLC on 
silica gel in 40% methanol/chloroform to give a pale yellow oil (0.090 g, 53%). Rf  
0.12  (40% methanol/chloroform). [α] 20D
 
+4736.8 (c = 0.019, methanol). IR (thin 
film)/cm
-1
 3354, 2970, 2776. [Note: Pyrrolidine ring derived from lactam is labelled 
pyrrolidine B and other is pyrrolidine A] 
1
H NMR  7.34-7.21 (m, 5H, aromatic), 3.24 
(q, 1H, J = 6.6 Hz, -CH), 3.01-2.88 (m, 3H, pyrrolidine B -CH2  and pyrrolidine A 
-CH2), 2.62-2.54 (m, 2H, pyrrolidine B -CH2  and pyrrolidine B -CH2), 2.37 (d, 
1H, J = 9.33 Hz, pyrrolidine B -CH2), 1.89-1.68 (m, 6H, pyrrolidine B -CH2, 
pyrrolidine A -CH2 and pyrrolidine A -CH2), 1.35 (d, 3H, J = 6.6 Hz, -CH3). 
13
C 
NMR  145.43 (ipso aromatic), 128.2 (meta), 127.0 (ortho), 126.7 (para), 68.21 
(spiro Cq), 65.5 (-CH), 64.8 (pyrrolidine B -CH2), 52.0 (pyrrolidine B -CH2), 45.2 
(pyrrolidine A -CH2), 38.2 (pyrrolidine A -CH2), 37.8 (pyrrolidine B -CH2), 24.7 
(pyrrolidine A -CH2), 23.6 (CH3, -CH3). Mass spectrum m/z [M+H] 231.1857 
(calculated for C15H23N2 231.1861). 
 
(5R)-7-((1’R)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14b). 
This was prepared from 13b, by the method used for 14a. 46% yield as a pale yellow 
oil. Rf  0.12  (40% methanol/chloroform). [α]
20
D
 
+3928.5 (c = 0.021, methanol). IR 
(thin film)/cm
-1
 3359, 2970, 2776. 
1
H NMR  7.35-7.21 (m, 5H, aromatic), 3.27 (q, 
1H, J = 6.6 Hz, -CH), 3.03-2.84 (m, 3H, pyrrolidineB -CH2  and pyrrolidineA -
CH2), 2.52 (d, 1H, J = 9.5 Hz, pyrrolidineB -CH2), 2.40 (d, 1H, J = 9.5 Hz, 
pyrrolidineB -CH2), 2.4-2.36 (m, 1H, pyrrolidineB -CH2), 1.94-1.74 (m, 6H, 
pyrrolidineB -CH2, pyrrolidineA -CH2 and pyrrolidineA -CH2), 1.35 (d, 3H, J = 
6.6 Hz, -CH3). 
13
C NMR   145.35 (ipso aromatic), 128.2 (meta), 127.1 (ortho), 
126.7 (para), 68.4 (spiro Cq), 65.3 (-CH), 64.3 (pyrrolidineB -CH2), 51.7 
(pyrrolidineB -CH2), 45.0 (pyrrolidineA -CH2), 37.9 (pyrrolidineA -CH2), 37.1 
(pyrrolidineB -CH2), 24.3 (pyrrolidineA -CH2), 22.8 (-CH3). Mass spectrum m/z 
[M+H] 231.1858 (calculated for C15H23N2 231.1861). 
 
(5R)-7-((1’S)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14c). 
This was prepared from 13c, by the method used for 14a. 48% yield as a pale yellow 
oil. Analytical data were the same as 14a. Mass spectrum m/z [M+H] 231.1864 
(calculated for C15H23N2 231.1861). 
 
(5S)-7-((1’S)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14d). 
This was prepared from 13d, by the method used for 14a. 43% yield as a pale yellow 
oil. Analytical data was the same as 14b. Mass spectrum m/z [M+H] 231.1871 
(calculated for C15H23N2 231.1861). 
 
X-Ray Crystallography: 
Suitable crystals of 15a and 15b for X-ray study were obtained from ethanol 
solutions. The data were collected at 150(2)K on a Bruker APEX CCD diffractometer. 
The structure was solved by direct methods and refined on F
2
 using all the 
reflections.
19
 All the non-hydrogen atoms were refined using anisotropic atomic 
displacement parameters and hydrogen atoms were inserted at calculated positions 
using a riding model. 
 
Compound 15a. Crystal data: C15H22Cl2N2Zn, M = 366.62, triclinic, a = 7.288(3), b 
= 10.862(5), c = 11.169(5) Å,  = 90.304(6)°,  = 103.671(5)°,  = 95.005(6)°, U = 
855.5(7) Å
3
, space group P1, Z = 2, μ(Mo-Kα) = 1.740 mm-1.  6662 data (5905 
unique, Rint = 0.0261) were measured in the range 1.88 < θ < 25.99˚. R1(I > 2σ(I)) = 
0.0376 and wR2(all data) = 0.0986. Goodness of fit on F
2
 = 1.004. CCDC No. 641381. 
 
Molecular Modelling: 
The energy of the conformations of 12a and 12b were minimised using the MM
+
 
molecular mechanics force field in HYPERCHEM 7.5. 
Supplementary Data. 
 
Crystallographic data for 15a has been deposited with the Cambridge 
Crystallographic Data Centre. Copies of this information may be obtained free of 
charge from deposit@ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk 
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Captions 
 
Figure 1. Ethylenediamine 1; trans-1,2-Diaminocyclohexane 2; (-)-Sparteine 3 and 
1,7-Diaza-spiro[4.5]decane 4. 
 
Figure 2: Cyclisation methods for proline-derived spirolactams.
8,10,11 
 
Figure 3. Energy minimised conformations of 12a (S,R) and 12b (R,R).
17 
 
Figure 4. X-ray crystal structure of spirodiamine-ZnCl2 complex 15a. 
 
Figure 5. Mukaiyama’s diamines 16, complexed to Sn(OTf)2
17
 and ZnCl2. 
 
 
Figures 
NH2H2N
N
N
NH2H2N
N
N
H
H
H
H
1
3
2
4
H
H
 
Figure 1. Ethylenediamine 1; trans-1,2-Diaminocyclohexane 2; (-)-Sparteine 3 and 
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Figure 2: Cyclisation methods for proline-derived spirolactams.
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Figure 3. Energy minimised conformations of 12a (S,R) and 12b (R,R).
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Figure 4. X-ray crystal structure of spirodiamine-ZnCl2 complex 15a. 
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Figure 5. Mukaiyama’s diamines 16, complexed to Sn(OTf)2
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 and ZnCl2. 
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Scheme 1: Reagents and conditions; (a) SOCl2, MeOH, reflux, 94%; (b) (Boc)2O, DMAP, Et3N, DCM, rt, 74%; 
(c) i) LiHMDS, THF, -78 oC, ii) allyl bromide, rt, 80%; (d) OsO4/NaIO4, THF:H2O (4:1), rt, 74%;
(e) i) RNH2, EtOH, ii) NaBH4, rt; (f) Toluene, reflux, 60-88%.
10a, R = -CH2CH=CH2
10b,     = -CH2Ph
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Scheme 2: Reagents and conditions; (a) i) (R)-1-phenylethylamine, MgSO4, MeOH, ii) NaBH4, rt; (b) NaNH2 in 
toluene, reflux, 30% from 4; (c) i) (S)-1-phenylethylamine, MgSO4, MeOH, ii) NaBH4, rt; (d) NaNH2 in toluene, reflux, 51% 
from 4.
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Scheme 3: Reagents and conditions; (a) i) 50% TFA in DCM, ii) 3 M KOH; (b) LiAlH4, THF, rt.
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Tables 
 
Table 1.  Selected bond lengths (Å) and angles (º) for 15a. 
 
Bond Bond lengths Angle Bond Angles 
Zn(1A)-N(1A) 2.067(5) N(1A)-Zn(1A)-N(2A) 84.4(2) 
Zn(1A)-N(2A) 2.104 6) N(1A)-Zn(1A)-Cl(1A) 113.11(16) 
Zn(1A)-Cl(1A) 2.213(2) N(2A)-Zn(1A)-Cl(1A) 117.00(16) 
Zn(1A)-Cl(2A) 2.2191(18) N(1A)-Zn(1A)-Cl(2A) 108.42(17) 
Zn(1B)-N(1B) 2.049(5) N(2A)-Zn(1A)-Cl(2A) 107.20(16) 
Zn(1B)-N(2B) 2.117(5) Cl(1A)-Zn(1A)-Cl(2A) 120.71(7) 
Zn(1B)-Cl(2B) 2.2118(19) N(1B)-Zn(1B)-N(2B) 84.4(2) 
Zn(1B)-Cl(1B) 2.213(2) N(1B)-Zn(1B)-Cl(2B) 109.46(16) 
  N(2B)-Zn(1B)-Cl(2B) 111.39(17) 
  N(1B)-Zn(1B)-Cl(1B) 110.69(17) 
  N(2B)-Zn(1B)-Cl(1B) 116.31(17) 
  Cl(2B)-Zn(1B)-Cl(1B) 119.11(7) 
 
